Cystic Fibrosis

Cystic Fibrosis News

  • Alert FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis Symdeko is for people aged 12 years and older who have two copies of the F508del mutation in the CFTR gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.
  • Corbus Cystic Fibrosis Drug to Get FDA Review on Flare-up Data Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

Cystic Fibrosis Perspective